BioSpace News Archive

According to the report, the global viscosupplementation market was valued at ~US$ 2.6 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027.

Biophytis SA announces the appointment of Rob van Maanen MD MBA as Chief Medical Officer, member of the Executive Committee.

GeneQuine Biotherapeutics GmbH announced that it has contracted Exothera S.A., a full-service Contract Development and Manufacturing Organization, to conduct a feasibility study for the development of a large-scale manufacturing process for its osteoarthritis gene therapy product candidate GQ-303 in the highly scalable scale-X™ fixed-bed bioreactor.

B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at its factory, for a compact proton cancer therapy system under development, and confirmed the generation of a magnetic field.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, provided an operational update and released financial results for the first fiscal quarter ended July 31, 2021.

PLx Pharma Inc. today announced that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present virtually at two upcoming healthcare conferences

Cybin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Sio Gene Therapies Inc. today announced dosing of the first Type I, or early infantile, patient in the low-dose cohort of its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis.

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat cellular energetic failure, announced the final patient visit has been completed in its Phase 2 RESCUE-ALS study and that trial close-out activities have begun.

SOPHiA GENETICS SA (NASDAQ: SOPH), today reported financial results for the three months ended June 30, 2021.